Yuva Biosciences applies AI to mitochondrial research to identify compounds that restore mitochondrial function; its first ingredient to market is YuvaBio® Y100™. Y100 is available for licensing to non-drug consumer brands and is being incorporated into BosleyMD’s Revive Plus Densifying Foam for national retail and e-commerce rollout. The company was founded in 2019 and is headquartered in Birmingham, Alabama. Yuva’s scientific leadership includes Co‑Founder and CSO Dr. Keshav K. Singh and CEO Greg Schmergel; the team also includes consumer-products veteran Dr. Shekhar Mitra. The company reports noticeable effects in multiple clinical trials and positions the platform to target additional mitochondrial-related indications such as ovarian aging and wound care. Financially, Yuva completed a $7.5M seed financing led by VentureSouth.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2024